AstraZeneca Affiliate Hit With $275M Merger Payment Suit

Law360, New York (June 22, 2017, 7:29 PM EDT) -- Agents for the former shareholders of a pharmaceutical company acquired by an affiliate of AstraZeneca PLC filed suit Thursday in Delaware state court seeking the payment of $275 million they allege is owed from the 2013 merger of the two companies.

In a Delaware Chancery Court complaint unsealed Thursday, David Kabakoff and Arnold Oronsky sued Zeneca Inc. on behalf of the former investors in Amplimmune Inc. seeking payment of $275 million in contingent consideration they say is due as part of the merger agreement. Amplimmune shareholders received $225 million in upfront payments in the deal, with the other $275 million coming...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!